NASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, July 9, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), announced today that it has been informed by the U.S. Food and Drug Administration (FDA) that the Circulatory System Devices Panel of the Medical Devices Advisory Committee will review the...
Read MoreCompany to Report Full Financial Results on August 6, 2020 NASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, July 6, 2020 – Neovasc, Inc. (NASDAQ, TSX: NVCN), today announced preliminary revenue results for the second quarter of 2020. Revenue for the quarter ended June 30, 2020 was approximately $295,000. Revenues...
Read MoreNASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, June 29, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today announced that the Neovasc Reducer™ (“Reducer”) and Tiara™ (“Tiara”) program were recently featured at two industry conferences. The Tiara Mitral Valve Replacement program was featured at both...
Read MoreNASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, June 26, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today announced positive interim results of the REDUCER-I study during the PCR E-Course. Stefan Verheye, M.D., PhD, ZNA Middelheim, Antwerp, Belgium presented the results of the trial during...
Read MoreNASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, June 25, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), announced that it received written notification yesterday (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum...
Read MoreNASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, June 16, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today that it has...
Read MoreNASDAQ, TSX: NVCN Vancouver, Canada, June 12, 2020 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 3,883,036 common shares at a...
Read MoreNASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, June 9, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc...
Read More